These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22485076)

  • 1. Advances in the treatment of hepatitis C virus infection.
    Jesudian AB; Gambarin-Gelwan M; Jacobson IM
    Gastroenterol Hepatol (N Y); 2012 Feb; 8(2):91-101. PubMed ID: 22485076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral therapies for chronic hepatitis C virus infection with cirrhosis.
    Nakamoto S; Kanda T; Shirasawa H; Yokosuka O
    World J Hepatol; 2015 May; 7(8):1133-41. PubMed ID: 26052402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current progress in the treatment of chronic hepatitis C.
    Alexopoulou A; Papatheodoridis GV
    World J Gastroenterol; 2012 Nov; 18(42):6060-9. PubMed ID: 23155334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid progression of antiviral treatments of chronic hepatitis C virus infection.
    Pol S; Corouge M; Mallet V; Sogni P
    Minerva Gastroenterol Dietol; 2013 Jun; 59(2):161-72. PubMed ID: 23831907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatitis C virus: 25 years-old, the end?].
    Pol S
    Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.
    Kanda T; Nakamoto S; Sasaki R; Nakamura M; Yasui S; Haga Y; Ogasawara S; Tawada A; Arai M; Mikami S; Imazeki F; Yokosuka O
    Int J Med Sci; 2016; 13(4):310-5. PubMed ID: 27076789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New antiviral agents for hepatitis C.
    Pawlotsky JM
    F1000 Biol Rep; 2012; 4():5. PubMed ID: 22403588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hepatitis C: perspectives.
    Pol S; Corouge M
    Med Mal Infect; 2014 Oct; 44(10):449-54. PubMed ID: 25174659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faldaprevir for the treatment of hepatitis C.
    Kanda T; Yokosuka O; Omata M
    Int J Mol Sci; 2015 Mar; 16(3):4985-96. PubMed ID: 25749475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct anti-HCV agents.
    Zhang X
    Acta Pharm Sin B; 2016 Jan; 6(1):26-31. PubMed ID: 26904396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral antiviral therapies for chronic hepatitis C infection.
    Pol S; Corouge M; Sogni P
    Ther Adv Infect Dis; 2013 Jun; 1(3):107-16. PubMed ID: 25165547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
    Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A
    Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Direct antiviral treatment strategies in chronic hepatitis C].
    Neumann-Haefelin C; Blum HE; Thimme R
    Dtsch Med Wochenschr; 2012 Jun; 137(25-26):1360-5. PubMed ID: 22653493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New hepatitis C therapies in clinical development.
    Vermehren J; Sarrazin C
    Eur J Med Res; 2011 Jul; 16(7):303-14. PubMed ID: 21813371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.